Last reviewed · How we verify
PERTZYE
At a glance
| Generic name | PERTZYE |
|---|---|
| Also known as | pancrelipase, Pancrelipase |
| Sponsor | AbbVie |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase 2 Study to Assess the Safety and Efficacy of ANG003 (PHASE2)
- Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) (PHASE1, PHASE2)
- Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency (PHASE2)
- Management of Steatorrhea in Children and Young Adults With Alagille Syndrome After Liver Transplantation (PHASE2)
- A Study on the Changes of Glucose Metabolism and Exocrine Function in Patients With Chronic Pancreatitis (EARLY_PHASE1)
- Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency (PHASE4)
- Effect of Enzyme Therapy on Protein Metabolism in Chronic Pancreatitis (NA)
- Pancrelipase With Nutritional Supplement in Patients at Risk of Malnutrition (EFFORT-ENZO) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |